ATE327242T1 - Neue purine - Google Patents
Neue purineInfo
- Publication number
- ATE327242T1 ATE327242T1 AT00986551T AT00986551T ATE327242T1 AT E327242 T1 ATE327242 T1 AT E327242T1 AT 00986551 T AT00986551 T AT 00986551T AT 00986551 T AT00986551 T AT 00986551T AT E327242 T1 ATE327242 T1 AT E327242T1
- Authority
- AT
- Austria
- Prior art keywords
- purines
- new
- new purines
- cancer
- compounds
- Prior art date
Links
- 150000003212 purines Chemical class 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical group [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
- C07F9/4012—Esters of acyclic acids which can have further substituents on alkyl substituted by B, Si, P or a metal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4025—Esters of poly(thio)phosphonic acids
- C07F9/405—Esters of poly(thio)phosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17216199P | 1999-12-17 | 1999-12-17 | |
| US17251099P | 1999-12-17 | 1999-12-17 | |
| US24078800P | 2000-10-16 | 2000-10-16 | |
| US09/740,619 US6420384B2 (en) | 1999-12-17 | 2000-12-18 | Proton pump inhibitors |
| US09/740,267 US20020103161A1 (en) | 1999-12-17 | 2000-12-18 | Novel heterocycles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE327242T1 true ATE327242T1 (de) | 2006-06-15 |
Family
ID=27538855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00986551T ATE327242T1 (de) | 1999-12-17 | 2000-12-18 | Neue purine |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1259520B1 (de) |
| JP (1) | JP2004501062A (de) |
| AT (1) | ATE327242T1 (de) |
| CA (1) | CA2394646A1 (de) |
| DE (1) | DE60028253T2 (de) |
| IL (1) | IL150060A0 (de) |
| WO (1) | WO2001044260A2 (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1377579B1 (de) * | 2000-10-31 | 2009-03-25 | Aventis Pharmaceuticals Inc. | Acyl- und sulfonylderivative 6,9-disubstitutierter 2-(trans-1,4-diaminocyclohexyl)-purine und ihre verwendung als antiproliferative mittel |
| WO2006136005A1 (en) * | 2005-05-16 | 2006-12-28 | Prometic Biosciences Inc. | Purine derivatives and their use for treatment of autoimmune diseases |
| US8071609B2 (en) * | 2005-08-11 | 2011-12-06 | Ariad Pharmaceuticals, Inc. | Unsaturated heterocyclic derivatives |
| JP2009504803A (ja) | 2005-08-22 | 2009-02-05 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Tlrアゴニスト |
| JP4517078B2 (ja) * | 2005-08-30 | 2010-08-04 | 独立行政法人産業技術総合研究所 | 新規ビスホスフィノイル化合物、その製造方法及びそれを有効成分とした医薬 |
| UA93548C2 (uk) | 2006-05-05 | 2011-02-25 | Айерем Елелсі | Сполуки та композиції як модулятори хеджхогівського сигнального шляху |
| EP2029597A4 (de) | 2006-05-31 | 2011-11-23 | Univ California | Purinanaloga |
| ES2456964T3 (es) | 2007-02-07 | 2014-04-24 | The Regents Of The University Of California | Conjugados de agonistas de TLR sintéticos y usos de los mismos |
| EP2142547A1 (de) | 2007-03-28 | 2010-01-13 | NeuroSearch A/S | Purinylderivate und ihre verwendung als kaliumkanalmodulatoren |
| US8268838B2 (en) | 2008-09-26 | 2012-09-18 | Neurosearch A/S | Substituted purinyl-pyrazole derivatives and their use as potassium channel modulators |
| PE20100362A1 (es) | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
| CA2743449C (en) | 2008-11-12 | 2016-10-18 | Ariad Pharmaceuticals, Inc. | Pyrazinopyrazines and derivatives as kinase inhibitors |
| KR20150033679A (ko) | 2012-06-26 | 2015-04-01 | 사니오나 에이피에스 | 페닐 트리아졸 유도체 및 이의 gabaa 수용체 복합체 조절용 용도 |
| NZ710444A (en) | 2013-02-11 | 2020-08-28 | Univ California | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy |
| CA2939219C (en) | 2014-02-11 | 2023-02-28 | Mitokinin Llc | Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease |
| US11697851B2 (en) | 2016-05-24 | 2023-07-11 | The Regents Of The University Of California | Early ovarian cancer detection diagnostic test based on mRNA isoforms |
| KR20200019228A (ko) | 2017-06-21 | 2020-02-21 | 미토키닌, 인크. | 신경퇴행성 및 미토콘드리아 질환의 치료를 위한 조성물 및 이를 사용하는 방법 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1017564B (it) * | 1974-04-30 | 1977-08-10 | Snam Progetti | Processo per la preparazione di derivati adeninici funzionalizza ti e prodotti cosi ottenuti |
| US5688778A (en) * | 1989-05-15 | 1997-11-18 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Nucleoside analogs |
| CA2479846C (en) * | 1989-05-15 | 2007-07-24 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Scienc Es Of The Czech Republic | Phosphonomethoxymethylpurine/pyrimidine derivatives |
| GB9020932D0 (en) * | 1990-09-26 | 1990-11-07 | Wellcome Found | Heterocyclic compounds |
| EP0531597A1 (de) * | 1991-09-12 | 1993-03-17 | Merrell Dow Pharmaceuticals Inc. | Ungesättigte azyklische Phosphonsäure Purinderivats und Pyrimidinderivate |
| US5849905A (en) * | 1994-11-23 | 1998-12-15 | Centre National De La Recherche Scientifique | Biologically active phosphotriester-type nucleosides and methods for preparing same |
| CA2224710A1 (en) * | 1995-06-15 | 1997-01-03 | Naoko Inoue | Phosphonate nucleotide derivatives |
| JP4118958B2 (ja) * | 1996-10-09 | 2008-07-16 | ファーマセット,リミティド | テトラホスホネート二環式トリス無水物 |
| WO1998039344A1 (en) * | 1997-03-07 | 1998-09-11 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
-
2000
- 2000-12-18 DE DE60028253T patent/DE60028253T2/de not_active Expired - Lifetime
- 2000-12-18 JP JP2001544750A patent/JP2004501062A/ja not_active Withdrawn
- 2000-12-18 WO PCT/US2000/034417 patent/WO2001044260A2/en not_active Ceased
- 2000-12-18 IL IL15006000A patent/IL150060A0/xx unknown
- 2000-12-18 EP EP00986551A patent/EP1259520B1/de not_active Expired - Lifetime
- 2000-12-18 CA CA002394646A patent/CA2394646A1/en not_active Abandoned
- 2000-12-18 AT AT00986551T patent/ATE327242T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2394646A1 (en) | 2001-06-21 |
| WO2001044260A3 (en) | 2002-01-03 |
| WO2001044260A2 (en) | 2001-06-21 |
| WO2001044260A8 (en) | 2003-01-03 |
| EP1259520A2 (de) | 2002-11-27 |
| EP1259520B1 (de) | 2006-05-24 |
| IL150060A0 (en) | 2002-12-01 |
| WO2001044260A9 (en) | 2002-07-04 |
| DE60028253D1 (de) | 2006-06-29 |
| JP2004501062A (ja) | 2004-01-15 |
| DE60028253T2 (de) | 2007-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60028253D1 (de) | Neue purine | |
| NZ508268A (en) | Bicyclic pyrimidines and bicyclic 3,4- dihydropyrimidines as inhibitors of cellular proliferation | |
| IL151132A0 (en) | Pteridine compounds for the treatment of psoriasis | |
| ATE309223T1 (de) | Cyclin-abhängige kinase inhibitoren | |
| NO984718L (no) | Irreversible inhibitorer for tyrosin-kinaser | |
| JO2248B1 (en) | Pirazolobenzodiazepines | |
| NO20005885L (no) | Kombinasjonsterapi for behandling av refraktær depresjon | |
| NO20005884D0 (no) | Kombinasjonsterapi for behandling av bipolare forstyrrelser | |
| NO20034780D0 (no) | Antiangiogenisk kombinasjonsterapi for behandling av kreft | |
| EP1077704A4 (de) | Kombinationstherapie zur behandlung der depression | |
| NO20040516L (no) | Kombinasjonsterapi for behandling av kreft. | |
| ATE242234T1 (de) | Bicyclische arylcarboxamide und ihre therapeutische verwendung | |
| NO20020358D0 (no) | Anvendelse av etodolac for behandling av kreft | |
| ZA973622B (en) | Use of forms of hyaluronic acid (HA) for the treatment of cancer. | |
| DE69823493D1 (de) | Tetrahydropyridoverbindungen | |
| ID27214A (id) | Triazolopiridina untuk pengobatan gangguan trombosis | |
| BR0012921A (pt) | Compostos calcilìticos | |
| DE59902666D1 (de) | Edelfosin zur behandlung von hirntumoren | |
| IT1278858B1 (it) | Strumentario per il trattamento di fratture articolari della caviglia | |
| IL139144A0 (en) | Mycobacterial inhibitors | |
| DE19983519T1 (de) | Vorrichtung zur Wärmebehandlung von Körpergewebe | |
| YU22802A (sh) | Izonipekotamidi za lečenje poremećaja nastalih posredstvom integrina | |
| IT1320192B1 (it) | Composizione terapeutica per la cura della psoriasi. | |
| ID24922A (id) | Terapi kombinasi untuk pengobatan aids | |
| NO984430D0 (no) | Anvendelse av en inhibitor av Na+/H+-utveksler for fremstilling av medikament for behandling av profylakser av sykdommer i sentralnervesystemet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |